IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.323
EU - Europa 18.389
AS - Asia 8.900
SA - Sud America 1.851
AF - Africa 211
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 12
Totale 52.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.068
GB - Regno Unito 4.290
RU - Federazione Russa 3.943
CN - Cina 3.117
SG - Singapore 2.800
IE - Irlanda 2.555
IT - Italia 1.852
BR - Brasile 1.584
SE - Svezia 1.304
UA - Ucraina 1.194
DE - Germania 1.190
HK - Hong Kong 937
FR - Francia 824
VN - Vietnam 605
FI - Finlandia 535
KR - Corea 521
IN - India 277
ES - Italia 163
CA - Canada 126
AR - Argentina 105
BD - Bangladesh 103
BE - Belgio 93
NL - Olanda 85
AT - Austria 82
TR - Turchia 80
ZA - Sudafrica 78
MX - Messico 77
JP - Giappone 68
PL - Polonia 62
IQ - Iraq 61
EC - Ecuador 51
ID - Indonesia 49
CZ - Repubblica Ceca 36
PK - Pakistan 34
UZ - Uzbekistan 32
LT - Lituania 30
AU - Australia 24
SA - Arabia Saudita 24
VE - Venezuela 24
CO - Colombia 23
AE - Emirati Arabi Uniti 22
IR - Iran 21
CL - Cile 20
CI - Costa d'Avorio 18
EG - Egitto 18
MA - Marocco 17
EE - Estonia 16
LU - Lussemburgo 16
GR - Grecia 15
PY - Paraguay 15
KE - Kenya 14
KZ - Kazakistan 14
PA - Panama 13
JO - Giordania 12
SK - Slovacchia (Repubblica Slovacca) 12
AZ - Azerbaigian 11
IL - Israele 11
TH - Thailandia 11
UG - Uganda 11
MY - Malesia 10
PE - Perù 10
PH - Filippine 10
RS - Serbia 10
UY - Uruguay 10
DK - Danimarca 9
EU - Europa 9
NP - Nepal 9
RO - Romania 9
BG - Bulgaria 8
DO - Repubblica Dominicana 8
KG - Kirghizistan 8
LV - Lettonia 8
PT - Portogallo 8
TN - Tunisia 8
ET - Etiopia 7
JM - Giamaica 7
LB - Libano 7
AL - Albania 6
BO - Bolivia 6
BY - Bielorussia 6
CH - Svizzera 6
DZ - Algeria 6
TW - Taiwan 6
BH - Bahrain 5
GE - Georgia 5
HU - Ungheria 5
MW - Malawi 5
AM - Armenia 4
GT - Guatemala 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
OM - Oman 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BW - Botswana 3
CR - Costa Rica 3
GA - Gabon 3
GH - Ghana 3
Totale 52.650
Salva come PNG Salva come JPEG
Città #
Southend 3.754
Dallas 3.034
Fairfield 2.523
Dublin 2.522
Houston 1.662
Ashburn 1.624
Chandler 1.527
Singapore 1.520
Woodbridge 1.132
Moscow 1.049
Santa Clara 1.044
Jacksonville 972
Seattle 938
Wilmington 931
Hong Kong 922
Ann Arbor 857
Cambridge 854
Beijing 827
Siena 610
Seoul 515
Hefei 497
Munich 469
Princeton 437
Nanjing 297
New York 293
Los Angeles 290
Helsinki 240
Menlo Park 228
The Dalles 215
Dong Ket 187
Boardman 184
San Mateo 183
Ho Chi Minh City 155
Milan 146
São Paulo 142
San Diego 139
Buffalo 136
Shanghai 118
Rome 114
Bengaluru 113
Columbus 113
Nanchang 113
Málaga 110
Redondo Beach 105
London 93
Dearborn 92
Council Bluffs 87
Hanoi 87
Brussels 82
Düsseldorf 73
Tianjin 69
Nuremberg 65
Turku 62
Shenyang 60
Tokyo 57
Chicago 54
Florence 53
Vienna 52
Hebei 51
Changsha 49
Frankfurt am Main 49
Warsaw 49
Hangzhou 47
Toronto 47
Rio de Janeiro 46
San Francisco 46
Atlanta 44
Denver 44
Phoenix 44
Johannesburg 42
Jiaxing 41
Lancaster 41
Lappeenranta 41
Montreal 40
Portsmouth 40
Belo Horizonte 39
Brooklyn 39
Chennai 39
Zhengzhou 38
Jinan 37
Kunming 37
Norwalk 37
Bologna 34
Guangzhou 34
Lauterbourg 34
Brasília 32
Stockholm 32
Amsterdam 31
Mexico City 31
Falls Church 30
Da Nang 28
Fremont 28
Redwood City 28
Tashkent 28
Dhaka 27
Izmir 27
Manchester 27
Poplar 26
Boston 25
Orem 25
Totale 36.381
Salva come PNG Salva come JPEG
Nome #
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 602
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 596
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 529
Surrogate markers as a guide to evaluate response to antiretroviral therapy 465
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 300
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 299
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 290
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 290
A child with vestibular neuritis. Is adenovirus implicated? 283
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 283
A novel methodology for large-scale phylogeny partition 277
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 277
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 277
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 270
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 264
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 257
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 256
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 255
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 254
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 253
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 252
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 252
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 252
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 249
Anticipating policy considerations for a future HIV vaccine: a preliminary study 248
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 247
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 246
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 243
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 241
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 239
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 238
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 238
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 236
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 234
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 234
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 233
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 231
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 230
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 229
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 229
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 228
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 228
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 228
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 228
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 225
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 224
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 223
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 222
HIV-1 and human myelin proteins share an antigenic determinant 221
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples 220
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 219
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 219
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 218
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 218
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 218
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 218
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 217
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 216
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 216
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 216
Focal myositis: a polymerase chain reaction analysis for a viral etiology 215
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 214
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 214
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 213
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 213
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 212
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 210
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 210
Biotechnology for virus vaccine design, production, and control 210
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 210
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 208
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 206
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 206
An update to the HIV-TRePS system: The development of new computational models that do not require a genotype to predict HIV treatment outcomes 203
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 201
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 200
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 200
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 199
Advantages of Predicted Phenotypes and Statistical Learning Models in Inferring Virological Response to Antiretroviral Therapy from HIV Genotype 198
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 197
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 197
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. 197
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 195
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 195
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 195
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 194
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 194
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 193
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 192
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 189
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America 187
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 187
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 186
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 184
Dosage of Tn916 circular intermediates in Enterococcus faecalis 184
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 184
First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing 184
The global spread of HIV-1 subtype B epidemic 182
Only slight impact of predicted replicative capacity for therapy response prediction 181
European guidelines on the clinical management of HIV-1 tropism testing 181
Totale 23.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 169.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 169.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.318 0 0 0 0 0 535 417 709 481 412 304 460
2021/20223.917 213 471 270 404 199 148 210 174 301 400 362 765
2022/20235.270 317 517 621 730 510 1.036 148 434 494 159 203 101
2023/20243.752 159 99 318 214 79 1.091 1.286 103 18 63 82 240
2024/20258.806 190 403 841 427 1.010 554 377 565 816 436 912 2.275
2025/202613.398 1.658 2.774 2.650 2.298 3.826 192 0 0 0 0 0 0
Totale 53.505